HELSINKI, 28-Nov-2019 — /EuropaWire/ — NIB signs new loan agreement of DKK 450 million (EUR 60 million) with Danish hearing healthcare company Demant A/S to finance Demant’s research investments for 2019. This is the third loan agreed between NIB and Demant since 2015.
The seven-year loan finances in part Demant’s current R&D programme on the advancement of new audiological technology and on improving the design, computational powers and durability of hearing aid devices to improve user experiences.
Due to demographic change and better diagnostics, global demand for hearing aids is increasing.
Demant has close collaboration with universities, research centres and the corporate sector to develop hearing healthcare technology. Demand also has its own research facility, Eriksholm, dedicated to pursuing audiological innovations.
Demant A/S is a global leader in modern hearing healthcare solutions based in Denmark. Damant’s product range includes hearing aids, diagnostic instruments, hearing implants and audio solutions in areas such as enterprise communication and gaming.
NIB is owned by eight member countries: Denmark, Estonia, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. The international financial institution finances private and public projects in and outside the member countries. NIB has the highest possible credit rating, AAA/Aaa, with the leading rating agencies Standard & Poor’s and Moody’s.
Mr Vagn Lundhøj, Senior Manager, Origination, at +358 10 618 0370, email@example.com
Ms Lisa-Maria Altenberger, Communications Unit, at +358 10 618 0234, firstname.lastname@example.org